Predicine

Predicine is a global molecular insights company that focuses on advancing precision medicine in oncology. The company has developed a breakthrough cell-free DNA- and cell-free RNA-based liquid biopsy technology, enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. Predicine has launched a portfolio of blood-, urine- and tissue-based diagnostic assays for oncology. With business operations in Silicon Valley, Houston, Shanghai, Singapore, and Boston, Predicine collaborates with leading biopharma companies, institutions, and governments to support personalized healthcare globally. Since its establishment in 2015, the company operates within the Biotechnology, Health Care, and Life Sciences industries. While specific details about the last investment and investors are not available, Predicine's innovative approach and international presence position it as an intriguing player in the advancement of precision medicine.